"I think we're too often fixated on numbers, and not enough on what outcomes they relate to, " says Clifford Rosen, a top expert on bone disease at the Jackson Laboratory in Barr Harbor, Maine, who headed an FDA advisory panel on Avandia.

FORBES: Magazine Article